Selected research
Industry Research
Venous Thromboembolism Drug Industry Research Report 2026
Market perspective
The global Venous Thromboembolism Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Venous Thromboembolism Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Venous Thromboembolism Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Venous Thromboembolism Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Venous Thromboembolism Drug include Sanofi, J&J, Bayer, Gamma Therapeutics, eXIthera Pharmaceuticals, Daiichi Sankyo, Boehringer Ingelheim, BMS and BioInvent, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Venous Thromboembolism Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Venous Thromboembolism Drug Market by Company
Sanofi
J&J
Bayer
Gamma Therapeutics
eXIthera Pharmaceuticals
Daiichi Sankyo
Boehringer Ingelheim
BMS
BioInvent
Aspen Pharma
Armetheon
Altor Bioscience
Venous Thromboembolism Drug Segment by Type
Rivaroxaban
Warfarin
Heparin
Dabigatran
Edaxaban
Apixaban
Venous Thromboembolism Drug Segment by Application
Hospital
Clinic
Venous Thromboembolism Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Venous Thromboembolism Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Venous Thromboembolism Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Venous Thromboembolism Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Venous Thromboembolism Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Venous Thromboembolism Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Venous Thromboembolism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Rivaroxaban
- Warfarin
- Heparin
- Dabigatran
- Edaxaban
- Apixaban
Applications
- Hospital
- Clinic
Companies covered
- Sanofi
- J&J
- Bayer
- Gamma Therapeutics
- eXIthera Pharmaceuticals
- Daiichi Sankyo
- Boehringer Ingelheim
- BMS
- BioInvent
- Aspen Pharma
- Armetheon
- Altor Bioscience
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Venous Thromboembolism Drug Market Size (2021-2032)
- 2.2.2 Global Venous Thromboembolism Drug Sales (2021-2032)
- 2.2.3 Global Venous Thromboembolism Drug Market Average Price (2021-2032)
- 2.3 Venous Thromboembolism Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Rivaroxaban
- 2.3.3 Warfarin
- 2.3.4 Heparin
- 2.3.5 Dabigatran
- 2.3.6 Edaxaban
- 2.3.7 Apixaban
- 2.4 Venous Thromboembolism Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Venous Thromboembolism Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Venous Thromboembolism Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Venous Thromboembolism Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Venous Thromboembolism Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Venous Thromboembolism Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Venous Thromboembolism Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Venous Thromboembolism Drug, Product Type & Application
- 3.8 Global Manufacturers of Venous Thromboembolism Drug, Established Date
- 3.9 Global Venous Thromboembolism Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sanofi
- 4.1.1 Sanofi Company Information
- 4.1.2 Sanofi Business Overview
- 4.1.3 Sanofi Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sanofi Venous Thromboembolism Drug Product Portfolio
- 4.1.5 Sanofi Recent Developments
- 4.2 J&J
- 4.2.1 J&J Company Information
- 4.2.2 J&J Business Overview
- 4.2.3 J&J Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 J&J Venous Thromboembolism Drug Product Portfolio
- 4.2.5 J&J Recent Developments
- 4.3 Bayer
- 4.3.1 Bayer Company Information
- 4.3.2 Bayer Business Overview
- 4.3.3 Bayer Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bayer Venous Thromboembolism Drug Product Portfolio
- 4.3.5 Bayer Recent Developments
- 4.4 Gamma Therapeutics
- 4.4.1 Gamma Therapeutics Company Information
- 4.4.2 Gamma Therapeutics Business Overview
- 4.4.3 Gamma Therapeutics Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Gamma Therapeutics Venous Thromboembolism Drug Product Portfolio
- 4.4.5 Gamma Therapeutics Recent Developments
- 4.5 eXIthera Pharmaceuticals
- 4.5.1 eXIthera Pharmaceuticals Company Information
- 4.5.2 eXIthera Pharmaceuticals Business Overview
- 4.5.3 eXIthera Pharmaceuticals Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 eXIthera Pharmaceuticals Venous Thromboembolism Drug Product Portfolio
- 4.5.5 eXIthera Pharmaceuticals Recent Developments
- 4.6 Daiichi Sankyo
- 4.6.1 Daiichi Sankyo Company Information
- 4.6.2 Daiichi Sankyo Business Overview
- 4.6.3 Daiichi Sankyo Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Daiichi Sankyo Venous Thromboembolism Drug Product Portfolio
- 4.6.5 Daiichi Sankyo Recent Developments
- 4.7 Boehringer Ingelheim
- 4.7.1 Boehringer Ingelheim Company Information
- 4.7.2 Boehringer Ingelheim Business Overview
- 4.7.3 Boehringer Ingelheim Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Boehringer Ingelheim Venous Thromboembolism Drug Product Portfolio
- 4.7.5 Boehringer Ingelheim Recent Developments
- 4.8 BMS
- 4.8.1 BMS Company Information
- 4.8.2 BMS Business Overview
- 4.8.3 BMS Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 BMS Venous Thromboembolism Drug Product Portfolio
- 4.8.5 BMS Recent Developments
- 4.9 BioInvent
- 4.9.1 BioInvent Company Information
- 4.9.2 BioInvent Business Overview
- 4.9.3 BioInvent Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 BioInvent Venous Thromboembolism Drug Product Portfolio
- 4.9.5 BioInvent Recent Developments
- 4.10 Aspen Pharma
- 4.10.1 Aspen Pharma Company Information
- 4.10.2 Aspen Pharma Business Overview
- 4.10.3 Aspen Pharma Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Aspen Pharma Venous Thromboembolism Drug Product Portfolio
- 4.10.5 Aspen Pharma Recent Developments
- 4.11 Armetheon
- 4.11.1 Armetheon Company Information
- 4.11.2 Armetheon Business Overview
- 4.11.3 Armetheon Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Armetheon Venous Thromboembolism Drug Product Portfolio
- 4.11.5 Armetheon Recent Developments
- 4.12 Altor Bioscience
- 4.12.1 Altor Bioscience Company Information
- 4.12.2 Altor Bioscience Business Overview
- 4.12.3 Altor Bioscience Venous Thromboembolism Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Altor Bioscience Venous Thromboembolism Drug Product Portfolio
- 4.12.5 Altor Bioscience Recent Developments
5 Global Venous Thromboembolism Drug Market Scenario by Region
- 5.1 Global Venous Thromboembolism Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Venous Thromboembolism Drug Sales by Region: 2021-2032
- 5.2.1 Global Venous Thromboembolism Drug Sales by Region: 2021-2026
- 5.2.2 Global Venous Thromboembolism Drug Sales by Region: 2027-2032
- 5.3 Global Venous Thromboembolism Drug Revenue by Region: 2021-2032
- 5.3.1 Global Venous Thromboembolism Drug Revenue by Region: 2021-2026
- 5.3.2 Global Venous Thromboembolism Drug Revenue by Region: 2027-2032
- 5.4 North America Venous Thromboembolism Drug Market Facts & Figures by Country
- 5.4.1 North America Venous Thromboembolism Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Venous Thromboembolism Drug Sales by Country (2021-2032)
- 5.4.3 North America Venous Thromboembolism Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Venous Thromboembolism Drug Market Facts & Figures by Country
- 5.5.1 Europe Venous Thromboembolism Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Venous Thromboembolism Drug Sales by Country (2021-2032)
- 5.5.3 Europe Venous Thromboembolism Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Venous Thromboembolism Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Venous Thromboembolism Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Venous Thromboembolism Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Venous Thromboembolism Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Venous Thromboembolism Drug Market Facts & Figures by Country
- 5.7.1 South America Venous Thromboembolism Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Venous Thromboembolism Drug Sales by Country (2021-2032)
- 5.7.3 South America Venous Thromboembolism Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Venous Thromboembolism Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Venous Thromboembolism Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Venous Thromboembolism Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Venous Thromboembolism Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Venous Thromboembolism Drug Sales by Type (2021-2032)
- 6.1.1 Global Venous Thromboembolism Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Venous Thromboembolism Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Venous Thromboembolism Drug Revenue by Type (2021-2032)
- 6.2.1 Global Venous Thromboembolism Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Venous Thromboembolism Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Venous Thromboembolism Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Venous Thromboembolism Drug Sales by Application (2021-2032)
- 7.1.1 Global Venous Thromboembolism Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Venous Thromboembolism Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Venous Thromboembolism Drug Revenue by Application (2021-2032)
- 7.2.1 Global Venous Thromboembolism Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Venous Thromboembolism Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Venous Thromboembolism Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Venous Thromboembolism Drug Value Chain Analysis
- 8.1.1 Venous Thromboembolism Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Venous Thromboembolism Drug Production Mode & Process
- 8.2 Venous Thromboembolism Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Venous Thromboembolism Drug Distributors
- 8.2.3 Venous Thromboembolism Drug Customers
9 Global Venous Thromboembolism Drug Analyzing Market Dynamics
- 9.1 Venous Thromboembolism Drug Industry Trends
- 9.2 Venous Thromboembolism Drug Industry Drivers
- 9.3 Venous Thromboembolism Drug Industry Opportunities and Challenges
- 9.4 Venous Thromboembolism Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst